The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Olysio was produced by Janssen.
On the downside, hepatitis C therapy Olysio/Sovriad (simeprevir) continued its decline in the face of strong competition in the marketplace from Gilead and AbbVie, falling 86% to just $32m in
to $8.1bn despite heavy competition to hepatitis C therapies Olysio (simeprevir) and Incivo (telaprevir) from Gilead and AbbVie.
disease and arthritis drug Remicade (infliximab) and Olysio (simeprevir) for hepatitis C virus offset by growth in newer products. ... Olysio continued its slide in the face of competition from new HCV drugs from Gilead and AbbVie, with sales dropping
Meanwhile, for Olysio (simeprevir) - one of several new oral drugs that mark a major step forward in hepatitis C treatment - it was an innovative 'pay-if-you-clear' scheme that persuaded
Drugs such as AbbVie's Exviera (dasabuvir), Johnson &Johnson's Olysio (simprevir), Gilead's Sovaldi (sofosbuvir) and Bristol-Myers Squibb's Daklinza (daclatasvir) have essentially revolutionised treatment, but the latter two
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...